An in vitro binding assay which differentiates benzodiazepine 'agonists' and 'antagonists'

Phil Skolnick, Margaret M. Schweri, Evan F. Williams, Victoria Y. Moncada, Steven M. Paul

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

An in vitro test which discriminates benzodiazepine 'agonists' and 'antagonists' has been developed by exploiting the apparent differences in modulation of the benzodiazepine receptor by these classes of compounds. In the presence of 10 μM GABA, the potency of benzodiazepine 'agonists' (i.e., compounds which bind to the benzodiazepine receptor with a relatively high affinity and share pharmacologic properties with benzodiazepines) to displace [3H]3-carboethoxy-β-carboline is significantly increased. In contrast, the potency of benzodiazepine 'antagonists' (compounds which have been demonstrated to antagonize some of the pharmacologic actions of benzodiazepines) is not altered by GABA. Several chemically diverse classes of compound have been examined in this test, and within the limited number of compounds examined, this test accurately predicts 'agonist' and 'antagonist' actions in vivo.

Original languageEnglish
Pages (from-to)133-136
Number of pages4
JournalEuropean Journal of Pharmacology
Volume78
Issue number1
DOIs
StatePublished - Feb 19 1982
Externally publishedYes

Keywords

  • 3-Carboethoxy-β-carboline
  • Benzodiazepine 'agonist'
  • Benzodiazepine 'antagonist'
  • GABA

Fingerprint Dive into the research topics of 'An in vitro binding assay which differentiates benzodiazepine 'agonists' and 'antagonists''. Together they form a unique fingerprint.

Cite this